West Pharmaceutical Services (WST) Total Current Liabilities (2009 - 2026)

West Pharmaceutical Services has disclosed Total Current Liabilities across 18 years of filings, most recently posting $674.0 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $674.0 million, up 27.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $674.0 million (up 27.97% YoY), and the FY2025 annual result was $654.9 million, up 18.99% from the prior year.
• Total Current Liabilities came in at $674.0 million for Q1 2026 at West Pharmaceutical Services, up from $654.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $674.0 million in Q1 2026 to a low of $456.7 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $565.1 million (2022), against an average of $577.8 million.
• Across the five-year window, Total Current Liabilities climbed 29.44% in 2023 and dropped 18.77% in 2025, its largest moves.
• West Pharmaceutical Services' Total Current Liabilities stood at $519.0 million in 2022, then climbed by 29.44% to $671.8 million in 2023, then fell by 18.07% to $550.4 million in 2024, then climbed by 18.99% to $654.9 million in 2025, then gained by 2.92% to $674.0 million in 2026.
• The last three Total Current Liabilities figures came in at $674.0 million (Q1 2026), $654.9 million (Q4 2025), and $635.4 million (Q3 2025), per Business Quant data.